Assessing Both Peripheral & CNS Disease Selection for Inflammasome Therapeutics with Preclinical Models: Which Patient Population Will Inflammasome Therapeutics Be Most Effective For?
Time: 2:31 pm
day: Workshop Day
Details:
During this session we will assess disease selection for inflammasome therapeutics, addressing the main remaining questions of where will inflammasome therapeutics be most effective and for which patient population?
Join the session to look at:
- Harnessing the appropriate preclinical models that are available for inflammatory and autoimmune disease to verify disease applications and understanding which models big pharma want to see data in
- Standardizing models across the field to overcome the limitations of inflammasome preclinical models
- Assessing peripheral vs CNS indications to navigate the patient selection
- Navigating which disease to go for first in a proof-of-concept to understand where to invest in for the first clinical validation
- Selecting disease through proof-of-concept or deciding to go for the disease with the bigger therapeutic benefit
- Discussing inflammasomes as the key to unlocking particular diseases to understand approachable and practical therapeutic development targets
